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undertook a systematic literature review of studies of GM-
CSF in patients with advanced melanoma (stage IIIB–IV). 
Of the 503 articles identified, 26 studies met the eligibility 
criteria. Most studies investigated the use of GM-CSF in 
combination with another treatment, such as peptide vac-
cines or chemotherapy, or as an adjuvant to surgery. Some 
clinical benefit was reported in patients who received GM-
CSF as an adjuvant to surgery, or in combination with other 
treatments. In general, outcomes for patients receiving pep-
tide vaccines were not improved with the addition of GM-
CSF. GM-CSF may be a valuable therapeutic adjuvant; 
however, further studies are needed, particularly head-
to-head comparisons, to confirm the optimal dosing regi-
men and clinical effectiveness in patients with advanced 
melanoma.
Keywords GM-CSF · Granulocyte–macrophage colony-
stimulating factor · Melanoma · Immunotherapy · Efficacy
Abbreviations
ANC  Absolute neutrophil count
CI  Confidence interval
CR  Complete response
DTH  Delayed-type hypersensitivity
DTIC  Dacarbazine
gp100  Glycoprotein 100
MART-1  Melanoma antigen recognized by T 
cells 1
MFG-E8  Milk fat globule epidermal growth 
factor 8
MHP  Melanoma helper peptide
MP  Melanoma peptide
MSS  Melanoma-specific survival
NED  No evidence of disease
NR  Not reached
Abstract Several immunomodulatory checkpoint inhibi-
tors have been approved for the treatment of patients with 
advanced melanoma, including ipilimumab, nivolumab 
and pembrolizumab. Talimogene laherparepvec is the first 
oncolytic virus to gain regulatory approval in the USA; 
it is also approved in Europe. Talimogene laherparepvec 
expresses granulocyte–macrophage colony-stimulating fac-
tor (GM-CSF), and with other GM-CSF-expressing onco-
lytic viruses in development, understanding the clinical rel-
evance of this cytokine in treating advanced melanoma is 
important. Results of trials of GM-CSF in melanoma have 
been mixed, and while GM-CSF has the potential to pro-
mote anti-tumor responses, some preclinical data suggest 
that GM-CSF may sometimes promote tumor growth. GM-
CSF has not been approved as a melanoma treatment. We 
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ORR  Overall response rate
PD  Progressive disease
PFS  Progression-free survival
PRISMA  Preferred reporting items for system-
atic reviews and meta-analyses
Q2W/Q3W/Q4W  Every 2/3/4 weeks
TRP-2  Tyrosine-related protein 2
Introduction
Malignant melanoma accounts for approximately 1 % of 
cancer deaths worldwide, equating to over 55,000 deaths 
from this tumor type in 2012 [1]. Guidelines for the treat-
ment of cutaneous melanoma recommend surgical resec-
tion for localized disease; however, for metastatic disease, 
systemic therapy is often required [2, 3]. The treatment 
landscape for advanced or metastatic melanoma has 
recently changed. Previously, patients received chemo-
therapy or, in some cases, IL-2 [4, 5]. In Europe, the use 
of IL-2 is usually recommended only in the context of a 
clinical trial; however, in patients with metastatic disease 
who do not have access to a clinical trial program or tar-
geted therapy, IL-2 can be prescribed [3]. In contrast, in the 
USA, IL-2 is approved for the treatment of patients with 
metastatic melanoma [6]. The introduction of novel tar-
geted therapies, such as BRAF and MEK inhibitors, and 
immunomodulatory checkpoint inhibitors, has improved 
outcomes for patients with advanced disease [7].
Several immunomodulatory agents work by overrid-
ing checkpoints in the cancer-immunity cycle, thus pro-
moting the elimination of tumor cells by the immune sys-
tem [8]. Ipilimumab, a monoclonal antibody that targets 
the CTLA-4 receptor, and the antibodies nivolumab and 
pembrolizumab, both of which target PD-1, have been 
approved in the USA and Europe [9–14]. In October 2015, 
ipilimumab was approved in the USA for adjuvant therapy 
in the treatment of patients with cutaneous melanoma with 
pathologic involvement of regional lymph nodes of more 
than 1 mm in diameter who have undergone complete 
resection, including total lymphadenectomy [9]. Ipili-
mumab has also been granted accelerated approval in the 
USA for use in combination with nivolumab for the treat-
ment of patients with unresectable or metastatic wild-type 
BRAF V600 tumors [11]. Antibodies against PD-L1 (dur-
valumab [15], avelumab [16] and atezolizumab [17]) are in 
clinical development.
More recently, oncolytic viruses expressing GM-CSF 
have been developed, and in 2015, talimogene laher-
parepvec, a modified herpes simplex virus type 1, became 
the first oncolytic virus to gain regulatory approval in the 
USA, where it is indicated for the local treatment of unre-
sectable cutaneous, subcutaneous (s.c.) and nodal lesions 
in patients with melanoma recurrent after initial surgery. 
It has not been shown to improve overall survival (OS) 
or to have an effect on visceral metastases [18]. Talimo-
gene laherparepvec is also approved in Europe for the 
treatment of adults with unresectable stage IIIB–IVM1a 
melanoma that is regionally or distantly metastatic with 
no bone, brain, lung or other visceral disease [19]. Tali-
mogene laherparepvec has a proposed dual mechanism 
of action: The introduction of oncolytic viral particles 
directly into the tumor causes tumor cell lysis and local 
expression of the gene encoding GM-CSF induces a sys-
temic immune response [20]. There is evidence that the 
virus causes regression of both the injected and uninjected 
lesions [21, 22]. In early preclinical studies of talimogene 
laherparepvec, anti-tumor responses were observed fol-
lowing injection of viruses with and without GM-CSF, 
but responses in non-injected tumors were observed only 
in mice that received the GM-CSF-expressing virus [22]. 
Other modified GM-CSF-expressing oncolytic viruses in 
early clinical development include JX-594 [23], CG0070 
[24] and Ad5/3-D24-GMCSF [25].
In the randomized phase 3 OncovexGM-CSF Pivotal Trial 
in Melanoma (OPTiM), talimogene laherparepvec was 
compared with s.c. GM-CSF in patients with stage IIIB–IV 
unresected melanoma [21]. Studies of talimogene laher-
parepvec in combination with other agents are underway 
in patients with advanced melanoma, including a phase 
2 study of talimogene laherparepvec in combination with 
ipilimumab [26] and a phase 1b/3 trial of talimogene laher-
parepvec in combination with pembrolizumab [27].
GM-CSF is a hematopoietic growth factor that has plei-
otropic effects on the immune system (Fig. 1). It plays an 
important role in the development and maturation of den-
dritic cells (DCs) and in the activation and proliferation 
of T cells [28]. In response to immune stimuli, GM-CSF 
is produced by a variety of cell types, such as fibroblasts, 
epithelial cells, macrophages, T cells and tumor cells [28]. 
It is an important mediator of the interaction between T 
cells and antigen-presenting cells (APCs) and is, there-
fore, essential for anti-tumorigenic responses [28]. Owing 
to its immunobiology, GM-CSF has been investigated in 
clinical trials as both a monotherapy and in combination 
therapies. GM-CSF (sargramostim) is approved in the USA 
for the prevention and treatment of chemotherapy-induced 
neutropenia and for hematopoietic stem cell mobilization 
[29]. Early studies have shown that it acts as an immune 
adjuvant to drive humoral and cellular anti-tumor responses 
[28]. GM-CSF also acts as a chemoattractant for immune 
cells such as neutrophils [30], which can inhibit or promote 
tumor activity, depending on the tumor microenvironment. 
Tumor-associated neutrophils can induce angiogenesis 
[31], support tumor growth and metastases and suppress the 
anti-tumor immune response by decreasing the activation 
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of CD8+ T cells [32, 33]. Therefore, in some instances, 
localized GM-CSF may have a detrimental effect, enabling 
tumor growth and progression.
One of the mechanisms of cancer immunotherapy is the 
protection of anti-tumor immune cells from the suppres-
sive effects of certain cell types, such as regulatory T cells 
(T-regs) and myeloid-derived suppressor cells (MDSCs). 
MDSCs are a heterogeneous population of cells that medi-
ate tumor-induced immune suppression. The expansion 
and recruitment of MDSCs is mediated by several soluble 
factors, including GM-CSF [34]. Therefore, there have 
been some concerns that therapeutic GM-CSF may have 
the potential to induce proliferation of these immunosup-
pressive cells [35]. MDSC induction has been examined 
in several murine tumor models. In one model, intratu-
moral injection of a vaccinia virus expressing GM-CSF 
had mixed effects on MDSCs: by itself, it increased tumor-
associated, but not systemic, MDSCs; co-administration 
with HER2/neu, however, significantly reduced splenic 
and tumoral MDSCs [36]. In a model of liver metastases, 
expansion of MDSCs was dependent on tumor-produced 
GM-CSF [37]. In contrast to these findings, a different 
model showed that GM-CSF administered in combination 
with peptide vaccines caused localized accumulation of 
DCs and tumor-specific T cells, but no significant increase 
in the proportion of MDSCs [38]. In another model, tumor 
infiltration by MDSCs was directly correlated with splenic 
GM-CSF transcript levels [39]. There is somewhat lim-
ited clinical evidence for GM-CSF-mediated induction 
of MDSCs in patients with melanoma. In a phase 2 study 
of patients with stage IIIC and IV melanoma, talimogene 
laherparepvec-treated lesions had lower levels of MDSCs 
than did specimens derived from patients who had under-
gone surgical resection [40]. In the same study, analysis 
of tumor-infiltrating lymphocytes using a MART-1 ELIs-
pot assay showed that talimogene laherparepvec induced a 
local antigen-specific effector T-cell response and systemic 
immunity against melanoma antigens. In another study, 
patients receiving GM-CSF in combination with peptide 
vaccines and TLR-9 showed that there was no signifi-
cant change from baseline in the proportion of circulating 
immunosuppressive cells (T-regs or MDSCs) after treat-
ment [41]. In a prospective trial, no change in MDSCs was 
observed in patients who received GM-CSF following sur-
gical resection [42].
There is some evidence to suggest that the dose of GM-
CSF is important in determining immune activation, but 
other regulatory mechanisms may underlie this process 
[43]. In normal conditions, GM-CSF induces milk fat glob-
ule epidermal growth factor protein 8 (MFG-E8), enabling 
APCs to phagocytose apoptotic cells, which in turn pro-
motes immune tolerance and may attenuate any anti-tumor 
responses [44]. In some tumor microenvironments, loss of 
immune homeostasis and downregulation of MFG-E8 can 
occur. In this situation, GM-CSF no longer induces toler-
ance through MFG-E8 and can instead elicit an anti-tumor 
response [44]. Therefore, MFG-E8 may act as a regulator 
of GM-CSF function.
Fig. 1  Pleiotropic role of GM-
CSF in tumor immunity [28, 
32, 33] GM-CSF, granulocyte–
macrophage colony-stimulating 
factor
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There are few studies reporting data from direct com-
parisons between GM-CSF and other treatments in patients 
with advanced melanoma. Therefore, we conducted a sys-
tematic review of the available evidence on efficacy, immu-
nological effects and safety of GM-CSF in adult patients 
with stage IIIB–IV melanoma.
Methods
Literature search
We systematically reviewed published English language 
studies according to a pre-specified protocol. We searched 
Embase (January 1, 2000–May 1, 2015) and PubMed 
(January 1, 2000–May 1, 2015). Abstracts from the annual 
congresses of the following organizations were searched 
for the period January 1, 2010–April 24, 2015: American 
Society of Clinical Oncology, European Association of 
Dermato-Oncology and Society for Melanoma Research. 
Complete search strings are listed in electronic supplemen-
tary material.
Inclusion/exclusion criteria
Studies were included if they enrolled adults (≥18 years 
old) with advanced melanoma (defined as stage IIIB–IV) 
who received treatment with GM-CSF as monotherapy, as 
part of combination therapy or in an adjuvant setting. Stud-
ies that used modified viruses, cell lines, plasmid DNA or 
complementary DNA (cDNA) to deliver GM-CSF were 
excluded. Studies of prevention or detection of mela-
noma, or those that included patients with non-cutaneous 
melanoma (e.g., ocular or mucosal melanoma), were also 
excluded.
Screening and data extraction
The systematic review process described here is compli-
ant with the 2009 preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) guidelines [45]. The 
titles and abstracts of studies identified in the initial search 
were screened by two independent reviewers to ascer-
tain whether they met the pre-specified inclusion criteria. 
Phase 1–4 studies, single-arm studies, observational stud-
ies, systematic reviews, meta-analyses and pooled analyses 
were included, but editorials, letters, case reports, guide-
lines, health technology assessment reports, economic 
evaluations, narrative reviews and research protocols were 
excluded from the final analyses.
For all studies that were deemed eligible for inclusion, 
and for those for which eligibility remained uncertain fol-
lowing the title/abstract screen, the full texts of the study 
manuscripts were reviewed by two independent reviewers 
to confirm or refute their eligibility. Data were extracted 
from full-text publications when available. Data from con-
gress abstracts were included unless the same data had also 
been published in a peer-reviewed manuscript, in which 
case only the latter was included in the analysis. A proto-
col amendment was made at this stage and studies in which 
fewer than 10 patients received GM-CSF were excluded to 
focus the analysis on larger studies.
Data analyses
All data were presented as reported by the authors of the 
publications analyzed. Mean or median values reported in 
the studies were used as a basis for summarizing the effi-
cacy, immunological effects and safety of GM-CSF.
Results
Systematic literature search
We identified 589 full-text articles and 44 congress 
abstracts (Fig. 2). Following removal of duplicates, 503 
records were analyzed based on title and abstract. At this 
stage, 371 studies were excluded. The full texts of the 
remaining articles were screened and a further 106 were 
excluded, leaving 26 records for analysis. Most were phase 
2 studies (n = 16), and there were six studies that actively 
compared GM-CSF with other treatments and three that 
made comparisons with historical controls.
The study designs and dosing schedules are described in 
Table 1.
Comparative studies
Overall, six of the included studies made direct compari-
sons between GM-CSF treatment and non-GM-CSF treat-
ments [46–51], and three studies compared patients treated 
with GM-CSF with historical controls who did not receive 
GM-CSF [52–54].
GM‑CSF in combination with systemic therapy
Significant improvements in OS in patients who received 
GM-CSF treatment as an adjuvant to systemic therapy 
were reported in two studies. A phase 2 randomized 
study reported significantly prolonged median OS when 
GM-CSF was added to ipilimumab compared with ipili-
mumab alone (17.5 vs. 12.7 months; P = 0.01) [49]. The 
1-year OS was also significantly improved in the GM-
CSF group compared with the group receiving ipilimumab 
alone (1-year OS: 68.9 vs. 52.9 %; P = 0.01), but median 
1019Cancer Immunol Immunother (2016) 65:1015–1034 
1 3
progression-free survival (PFS) was not significantly dif-
ferent between treatment arms (3.1 months each for the 
GM-CSF group and the ipilimumab group; P = 0.37) 
[49]. The response rates were similar between groups: 
15.5 and 14.8 % in the GM-CSF and ipilimumab-alone 
groups, respectively [49]. In this trial, significantly fewer 
grade 3–5 adverse events were reported in patients receiv-
ing GM-CSF in combination with ipilimumab than in those 
receiving ipilimumab alone (44.9 vs. 58.3 %; P = 0.04); 
however, there were high numbers of deaths in both treat-
ment groups. The improvements in OS observed in the 
GM-CSF group may not necessarily be due to increased 
efficacy when GM-CSF is added to ipilimumab. Reduced 
toxicity and the resulting lower treatment dropout rate in 
the GM-CSF arm may have contributed to the observed OS 
improvement, but this remains to be determined. Further-
more, it is unclear whether treatment discontinuation in the 
ipilimumab group was due to adverse events or other rea-
sons, such as disease progression [49].
In another phase 2 study, patients who received a novel 
GM-CSF-containing maintenance biochemotherapy regi-
men after induction biochemotherapy had significantly 
longer median OS than historical controls who had received 
an identical biochemotherapy regimen without GM-CSF 
(18.5 vs. 9.3 months; P = 0.0004) [53]. The median PFS 
was also significantly prolonged (GM-CSF, 8.1 months; 
historical controls, 5.9 months; P = 0.0015), and multivari-
ate analyses showed that maintenance biotherapy was pre-
dictive of PFS and OS [53].
Eroglu et al. [52] investigated the use of GM-CSF in 
combination with docetaxel and vinorelbine. The 1-year 
OS was 48.1 %, which was significantly higher than the 
predicted survival according to the Korn analysis for this 
patient group (24.3 %; P = 0.012) [52].
Fig. 2  Preferred reporting 
items for systematic reviews 
and meta-analyses flow diagram 
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Clinical Oncology; EADO, 
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Dermato-Oncology
S
cr
ee
ni
ng
In
cl
ud
ed
E
lig
ib
ili
ty
Embase
237 records
PubMed
352 records
Additional records from
congress abstract search
ASCO (n = 33), EADO (n = 4), SMR (n = 7)
44 records
Title/abstract screen
503 records
Duplicates removed
130 records 
Excluded: 371 records
• Wrong article type
• Wrong intervention
• Irrelevant outcome
• Wrong tumor type or pooled
patient population 
• Wrong disease stage
• Included patients with ocular or
mucosal melanoma
Selected for full-text evaluation
132 records
Excluded: 99 records
• Irrelevant outcome
• Wrong tumor type or pooled
patient population
• Wrong disease stage
• Included patients with ocular or
mucosal melanoma
• Duplicate data reported in congress
abstract and full text
Excluded based on patient number
(<10 patients): 7 records 
Selected for analysis
26 records
Id
en
tif
ic
at
io
n
1020 Cancer Immunol Immunother (2016) 65:1015–1034
1 3
Table 1  Overview of study designs and GM-CSF dosing schedules
Author (year) Study phase/type Number of patients enrolled GM-CSF dosing regimen
Comparator studies (GM‑CSF compared with non‑GM‑CSF treatment)
Schaed et al. [51] Phase not specified; randomized 31 40 μg i.d. at a single site for 10 days in combination 
with peptide vaccine
Hersey et al. [48] Phase 1/2 36 400 μg s.c.; Q2W in combination with peptide vac-
cine for six vaccinations
Markovic et al. [50] Phase 2; randomized 25 10 or 50 μg s.c. in combination with peptide vaccine; 
Q3W for eight cycles, then every 3 months for up 
to 1 year
Celis et al. [46] Phase 2; randomized 28 75 or 100 μg s.c. or no GM-CSF; in combination 
with peptide vaccine for up to nine vaccinations or 
until PD, excessive toxicity or patient refusal
Grotz et al. [47] Retrospective cohort study 317 250 μg s.c. every day for 14 days of each 28-day 
cycle as an adjuvant to surgery; treatment contin-
ued for 1–3 years or until recurrence
Hodi et al. [49] Phase 2; randomized 245 250 μg s.c. in combination with ipilimumab on days 
1–14 of each 21-day cycle
Historical comparator studies
Spitler et al. [54] Phase 2 51 125 μg/m2 s.c. as an adjuvant to surgery for 14 con-
secutive days of each 28-day cycle; treatment was 
continued for ≥1 year or until disease recurrence or 
significant toxicity
O’Day et al. [53] Phase 2 33 125 μg/m2 s.c. on days 1–14 (or 3–17 during pulsed 
cycles) for 12 cycles (28 days per cycle) following 
biochemotherapy
Comparator studies (GM‑CSF used in all arms)
Slingluff Jr et al. [69] Phase 2 39 110 μg i.d. and s.c. in combination with peptide 
vaccine on days 1, 8 and 15; these injections were 
divided between two injection sites. On days 29, 
36 and 43, one injection was given at the primary 
vaccination site only
Slingluff Jr et al. [70] Phase 2; randomized 175 110 μg i.d. and s.c. in combination with peptide 
vaccine on days 1, 8 and 15. On days 29, 36 and 
43, one injection was given at the primary vaccina-
tion site. Treatment was continued as six cycles of 
booster vaccinations Q3W for up to 2 years
Single‑arm studies
Scheibenbogen et al. [63] Phase 2 18 75 or 150 μg i.d. and s.c. on days 1–4 and repeated 
in weeks 2, 4 and 6 in combination with peptide 
vaccines. If PD was not observed at week 10, two 
more vaccines were given in week 10 and week 14
Groenewegen et al. [58] Phase 1/2 32 2.5 μg/kg s.c. on days 2–12 following chemotherapy
Weber et al. [61] Phase 2 31 Biochemotherapy: 125 μg/m2 (maximum dose 
250 μg) s.c. on days 6–17 of each 28-day cycle for 
up to eight cycles or beyond at the discretion of the 
treating physician
Fruehauf et al. [57] Not specified 10 250 mg/m2 s.c. on days 2–12 Q2W in combination 
with chemotherapy
Boasberg et al. [56] Not specified 54 Maintenance biotherapy: 125 μg/m2 s.c. on days 
1–14 of each cycle (treatment began 4 weeks after 
the first day of each qualifying patient’s last cycle 
of concurrent biochemotherapy)
Pilla et al. [68] Phase 2 38 75 μg s.c. on days −1, 0 and +1 for cycles 1 and 
2, then administered Q2W at the same time as a 
peptide vaccine
Bins et al. [64] Phase 1 11 100 μg s.c. in combination with tetanus toxoid and 
peptide vaccines weekly for 4 weeks
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GM‑CSF in combination with peptide vaccines
GM-CSF used in combination with peptide vaccines had 
no significant effect on survival in two randomized phase 2 
studies. In one study, median OS values for patients receiv-
ing no GM-CSF, GM-CSF 75 μg or GM-CSF 100 μg were 
10, 6 and 9 months, respectively. This peptide vaccine was 
deemed clinically ineffective [46]. The other study reported 
that the addition of low-dose GM-CSF to melanoma pep-
tide (MP) vaccines emulsified in Montanide ISA-51 did 
not improve median OS or median PFS [50]. In a phase 
1/2 study, no clinical responses were reported in patients 
receiving T-cell peptide epitopes with or without GM-CSF 
[48].
GM‑CSF in the adjuvant setting
In studies that included patients who received adjuvant 
GM-CSF following complete surgical resection, most of 
the participants had stage IIIB or higher disease [47, 54, 
55]. In a retrospective cohort study by Grotz et al. [47], 
adjuvant GM-CSF use was not associated with a signifi-
cant difference in disease-free or melanoma-specific sur-
vival (MSS); however, within a subgroup of patients with 
stage IIIC disease, a 52 % lower melanoma-specific mortal-
ity was reported in individuals receiving GM-CSF than in 
those who were under observation only (hazard ratio 0.48; 
P = 0.02). The low patient numbers and lack of important 
information on patient characteristics, such as mutation sta-
tus or subsequent therapy, make the interpretation of this 
data set difficult.
Spitler et al. [54] evaluated GM-CSF as an adjuvant 
therapy in patients who were at high risk of recurrence. 
Individuals had to have stage III disease with more than 
four positive nodes and a tumor larger than 3 cm in diam-
eter. Median OS was significantly prolonged in those who 
received GM-CSF compared with matched historical con-
trols (37.5 vs. 12.2 months; P = 0.001). The 1-year OS and 
2-year OS were also significantly higher in the GM-CSF 
group than in the control group (89 vs. 45 % [P = 0.001] 
and 64 vs. 15 % [P = 0.001], respectively) [54].
In another study, prolonged GM-CSF treatment was 
given to patients for at least 3 years following surgical 
resection. The 5-year MSS rates were 67 and 40 % for 
patients with stage III and IV disease, respectively [55]. 
The majority (62/98) of patients had one or more disease 
recurrences, of which over half were successfully excised 
[55].
ANC absolute neutrophil count, PD progressive disease, Q2W/Q3W/Q4W every 2/3/4 weeks
Table 1  continued
Author (year) Study phase/type Number of patients enrolled GM-CSF dosing regimen
Daud et al. [42] Phase 2 42 125 μg/m2 s.c. on days 1–14 of each 28-day cycle 
(maximum 13 cycles), as an adjuvant to surgery
Weide et al. [67] Phase 1/2 15 150 μg s.c. 24 h after mRNA injection in weeks 0, 2, 
4 and 6, then Q4W until week 34
Dillman et al. [66] Phase 2 56 500 μg s.c. weekly for 3 weeks, then monthly for 
5 months (for up to a total of 6 months or eight 
doses) in combination with autologous DCs
O’Day et al. [62] Phase 2 133 Concurrent biotherapy: 500 μg i.v. on days 6–16 or 
until ANC ≥5000/μL in each 21-day cycle. Main-
tenance biotherapy: 250 μg s.c. on days 1–14 every 
28 days for 12 cycles
Spitler et al. [55] Not specified 102 125 μg/m2 s.c. on days 1–14 of each 28-day cycle; 
treatment continued for ≥3 years or until unresect-
able recurrence, as an adjuvant to surgery
Gunturu et al. [59] Phase 2 20 250 μg/m2 s.c. daily from day 8 until ANC recovery, 
following chemotherapy
Locke et al. [60] Phase 2 20 250 μg/m2 s.c. on days 3–12 following chemo-
therapy or until WBC count recovery, whichever 
occurred first. Treatment cycles continued Q3W 
until progression or toxicity
Adamina et al. [65] Phase 1/2 16 5 μg/kg s.c. every 5 days in each 7-day cycle, alter-
nating between a week of treatment and a week of 
rest over two 7-week courses, in combination with 
vaccinia virus
Eroglu et al. [52] Phase 2 52 250 mg/m2 s.c. on days 2–12 Q2W in combination 
with chemotherapy
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Single‑arm studies
Overall, 16 studies in which GM-CSF was not compared 
with another treatment arm were included. These are sum-
marized in Table 2.
GM‑CSF in combination with chemotherapy
Several single-arm studies evaluated the use of GM-CSF 
in combination with chemotherapy [52, 56–62]. When 
docetaxel, vinorelbine and GM-CSF were administered in 
a study conducted by Fruehauf et al., the overall response 
rate (ORR) was 50 % and the median time to progression 
was 8 months [57]. In a similarly designed study, Eroglu 
et al. [52] reported an ORR of 15.4 %. Median OS and PFS 
were 320 and 134 days, respectively, and the clinical bene-
fit rate was 52 % [52]. In another study, cyclophosphamide 
and fludarabine were followed by high-dose IL-2 and GM-
CSF to facilitate granulocyte recovery [59]. The ORR was 
22.2 % and estimated median OS and PFS were 1.1 and 
0.25 years, respectively [59]. Weber et al. [61] administered 
daily oral temozolomide followed by biotherapy (GM-CSF 
in combination with IFN and IL-2) and reported an ORR of 
26 %. The median PFS was 4.9 months and the overall ben-
efit rate was 48 % [61]. In a phase 1/2 study, dacarbazine 
(DTIC) followed by GM-CSF, IL-2 and IFN-α resulted in 
an ORR of 32 % [58].
Two studies assessed biochemotherapy followed by 
maintenance biochemotherapy [56, 62]. Boasberg et al. 
stratified survival according to whether or not patients 
developed vitiligo: Median OS was 18.2 months in patients 
who developed vitiligo during treatment compared with 
8.5 months in those who did not (P = 0.027) [56]. O’Day 
et al. [62] used a similar treatment regimen, but with a 
higher dose of GM-CSF, and reported a median OS of 13.5 
months.
GM‑CSF in combination with peptide vaccines
Scheibenbogen et al. [63] administered GM-CSF at the 
same site as a peptide vaccine and reported limited clini-
cal efficacy. In another study, no objective responses were 
reported when GM-CSF was given in combination with a 
peptide vaccine [64]. More promising results were obtained 
in a phase 1/2 trial of an intranodal injection of recombi-
nant vaccinia virus followed by soluble peptides and GM-
CSF [65]. Mean OS was 1106 days in responsive patients 
and 696 days in non-responsive patients [65].
GM‑CSF in combination with other treatments
In a phase 2 trial of GM-CSF in combination with an 
autologous DC vaccine, 1-year OS and 5-year predicted 
OS were 85 and 54 %, respectively [66]. Despite this, no 
objective responses were recorded [66]. Weide et al. [67] 
reported no objective responses when autologous mRNA 
derived from individual metastasizing tumors was admin-
istered to patients.
GM‑CSF in the adjuvant setting
In a phase 2 trial, patients with stage IV disease who had 
undergone surgical resection were given a peptide vaccine 
and adjuvant GM-CSF followed by IFN-α. After one treat-
ment cycle, 55 % of patients had stable disease and 5 % 
were disease-free. The median OS was 583 days [68]. Two 
studies with similar designs also used GM-CSF as an adju-
vant to surgery. In one study, median OS was 65.3 months 
and median recurrence-free survival was 5.6 months [42]. 
In the other study, the 5-year MSS was 67 % for patients 
with stage III disease and 40 % for those with stage IV dis-
ease [55].
Evidence of immune activation by GM‑CSF
Most studies reported evidence of immune activation, and 
these data are summarized in Table 3. When GM-CSF 
was used in combination with a peptide vaccine, immu-
nization against peptide-specific antigens was observed. 
In a single-arm study, proliferative immune responses to 
six melanoma helper peptides (MHPs) were observed in 
81 % of patients [69]. In patients with stage IV disease, 
peptide vaccines with adjuvant GM-CSF generated CD8+ 
and CD4+ responses ranging from 0 to 41 % and from 5 
to 47 %, respectively, across treatment groups, and there 
was a significant association between CD4+ response and 
survival (P = 0.0045) [70]. When immune responses were 
analyzed by treatment group, CD8+ and CD4+ responses 
were observed in 29.3 % and 16.4–21.1 % of patients, 
respectively, in those receiving peptide vaccines with GM-
CSF and Montanide ISA-51 adjuvants [70]. Markovic 
et al. [50] reported twofold or greater increases from base-
line in the number of tetramer-positive cytotoxic T cells 
for at least one vaccine-specific peptide in 37.5 % (3/8) of 
patients who did not receive GM-CSF and in 22.2 % (2/9) 
and 57.1 % (4/7) of those who received GM-CSF 10 and 
50 μg, respectively. When GM-CSF was given in combina-
tion with a peptide vaccine in another phase 2 study, there 
were no differences in immunization efficacy across treat-
ment arms. Therefore, addition of GM-CSF was ineffective 
at enhancing immunogenicity in this study [46].
Adamina et al. [65] used GM-CSF as an adjuvant fol-
lowing intranodal injection of recombinant vaccinia virus 
and MPs. All patients had an immune response to the 
tumor-associated antigen epitope encoded by the vaccinia 
virus. Furthermore, all T cells were responsive to in vitro 
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stimulation with the epitopes melanoma antigen recog-
nized by T cells 1 (MART-1) and glycoprotein 100 (gp100) 
[65]. In another study, positive delayed-type hypersensitiv-
ity (DTH) reactions were observed in nine of 17 patients 
receiving GM-CSF with or without Montanide ISA-720 
and in three of 17 patients who did not receive GM-CSF 
[48]. More severe hypersensitivity reactions were observed 
in patients receiving GM-CSF and peptides alone than in 
those receiving GM-CSF and peptides together with Mon-
tanide ISA-720. This suggests that GM-CSF may be ben-
eficial only when peptides are not administered together 
with strong adjuvants [48].
Although signs of peptide-specific immune activation 
were present in most studies, it appears likely to be non-
functional due to the lack of correlation with anti-tumor 
responses [46]. Celis [46] suggest that the phenotypic evi-
dence of immunization in the absence of clinical activity 
observed in their study was a result of immune dysfunc-
tion illustrated by the abnormal cytokine profiles detected 
in peripheral blood. In another study, Schaed et al. [51] 
reported no T-cell responses in patients who received the 
peptide vaccine emulsified in Montanide ISA-51. In those 
who received the vaccine with the adjuvants QS-21 or 
GM-CSF, the T-cell response rates were 44.4 % (4/9) and 
50.0 % (4/8) of patients, respectively. Eight weeks after 
immunization, the median number of T cells reactive to the 
peptide vaccine was highest in the QS-21 adjuvant group 
(1/3125 cells) followed by the GM-CSF group (1/4545 
cells) and the Montanide ISA-51 group (1/14 000 cells). 
However, this increase was transient, and 2 weeks after 
completion of treatment, the median number of reactive T 
cells was not significantly increased in any of the treatment 
groups. In this study, clinical benefit was not analyzed, and 
the magnitude of T-cell response necessary for therapeu-
tic effects has yet to be determined [51]. In another study 
in which GM-CSF was used as an adjuvant to a peptide 
vaccine, a cytotoxic T-cell response was observed in only 
26.7 % (4/15) of patients receiving GM-CSF; these indi-
viduals did not have progressive disease (PD) at the time of 
analysis. Of those who did have PD, no immune reactivity 
against the peptide vaccine was observed. The majority of 
patients (61 %) discontinued the study early owing to dis-
ease progression [63].
GM-CSF enhanced the immune response to ipilimumab, 
as measured by activation of inducible costimulator (ICOS) 
T cells. In a phase 2 study evaluating ipilimumab with or 
without GM-CSF, the median change in CD8+ ICOS 
T cells was significantly greater in patients who received 
ipilimumab and GM-CSF than in those who received ipili-
mumab alone (0.5 vs. 0.4 %; P = 0.01) [49]. Groenewegen 
et al. [58] reported significant increases from baseline in the 
number of CD4+ (P < 0.001) and CD8+ (P = 0.007) cells 
and a minor increase in the number of natural killer (NK) 
cells when GM-CSF was used as an adjuvant to chemother-
apy. In another study, in which GM-CSF was given as an 
adjuvant to chemotherapy, induction of melanoma-specific 
T cells was observed in one of four evaluable patients. GM-
CSF was used to support granulocyte recovery in this study, 
and IL-2 was also given to patients at the same time [59].
When GM-CSF was combined with tumor-derived 
autologous heat-shock protein gp96, increased T-cell reac-
tions against autologous and allogeneic melanoma cells 
were observed relative to baseline in 53.8 % (7/13) and 
26.7 % (4/15) of patients, respectively. Increases in the 
number of NK cells were also observed in 61.1 % (11/18) 
of patients [68]. In another study of adjuvant GM-CSF fol-
lowing surgery, a transient increase in the levels of mature 
DCs in peripheral blood was observed following GM-CSF 
treatment, but levels normalized by 4 weeks after the start 
of treatment [42]. Furthermore, subsequent cycles of GM-
CSF treatment did not change the levels of mature DCs in 
peripheral blood [42].
Discussion
This is the first systematic review of the efficacy of GM-
CSF in patients with advanced melanoma. Most studies 
were phase 1 or 2, but study phase was not reported in 
some studies; no phase 3 data were available. The study 
groups varied in size, but most enrolled fewer than 50 
patients, and those that had multiple comparator arms often 
had fewer than 10 patients per treatment group. Further-
more, several studies used historical controls or calculated 
survival rates as comparators, which makes conclusions 
from these studies problematic. A range of dosing sched-
ules and routes of administration was used for GM-CSF, 
but GM-CSF was most often delivered by s.c. injection at a 
dose of 125–250 mg/m2.
There was some evidence of clinical benefit in patients 
who received GM-CSF in combination with ipilimumab 
[49] or as part of a chemotherapy-containing regimen [52, 
53, 56, 57, 59, 62]. Ipilimumab is an immunomodulatory 
checkpoint inhibitor and has an activating effect on the 
immune system [71]. Therefore, there may be an additive 
effect when GM-CSF is used with ipilimumab. Stimulation 
of DCs by GM-CSF upregulates costimulatory molecules 
that are expressed by DCs, which bind to and activate T 
cells; however, the presence of CTLA-4 on T cells inhib-
its this interaction. Simultaneous inhibition of CTLA-4 
and stimulation of DCs would, therefore, be expected to 
enhance T-cell responses [71]. The clinical benefit observed 
with the addition of GM-CSF may also be attributed to a 
reduction in the incidence of adverse events; thus, patients 
are able to receive more cycles of treatment than those who 
do not receive it. The potential synergy between immune 
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checkpoint inhibitors and GM-CSF is interesting and may 
warrant further investigation.
The role of chemotherapy in immune activation is less 
clear, although there is accumulating evidence to sug-
gest that off-target effects of chemotherapy may modulate 
the innate and adaptive arms of the immune system [72]. 
Chemotherapy can deplete immune cells because it is 
indiscriminate in killing rapidly dividing cells, and can also 
modulate the immune system through several mechanisms. 
First, it can reduce the number of tumor-induced suppres-
sor cells. Secondly, chemotherapy kills tumor cells, thereby 
increasing antigenicity and, thirdly, it may directly induce 
an effector response by activating T cells [72]. DTIC and 
vinblastine have been shown to induce DC maturation, 
thereby stimulating immunogenic tumor cell death [73, 74]. 
In one phase 2 study, the use of GM-CSF as an adjuvant to 
chemotherapy was shown to modulate the immune system 
by inducing CD4+ regulatory cells, CD8+ suppressor T 
cells and memory T cells following lymphodepletion [59]. 
Furthermore, in 25 % of evaluable patients, the circulating 
melanoma-specific CD8+ cell population was expanded 
[59]. Hence, a synergistic enhancement of the immune 
response may occur following administration of GM-CSF 
to patients receiving chemotherapy; however, many stud-
ies of chemotherapy in combination with GM-CSF did not 
report immunological endpoints. Therefore, it is difficult to 
draw conclusions on the efficiency of immune activation 
when these two therapies are used in combination.
Activation of the immune response may correlate with 
anti-tumor activity. Boasberg et al. assessed a novel bio-
chemotherapy regimen containing GM-CSF and IL-2 and 
reported that median OS was significantly improved in 
patients exhibiting immune activation, as indicated by the 
development of vitiligo [75], compared with those who did 
not develop the condition [56]. Antibodies against tyrosi-
nase-related protein-2, a protein highly expressed in cuta-
neous melanoma [76], were detected in a larger proportion 
of patients with vitiligo than in those without, suggesting 
increased autoimmunity against melanoma cells in those 
who developed vitiligo [56]. In another study, patients 
with immune activation following intranodal injection of a 
recombinant vaccinia virus were more likely to have a clin-
ical response than those who did not show signs of immune 
activation [65].
GM-CSF in combination with peptide vaccines showed 
limited activity. Although T-cell activation was observed 
in several studies, this was not accompanied by a clinical 
anti-tumor response [46, 50, 63]. Furthermore, the immune 
induction observed may be transient, as observed in one 
study [51]. Although not eligible for inclusion in this sys-
tematic review, because it did not report data for our tar-
get population separately, a phase 2 randomized study 
of patients with stage IIB–IV resected melanoma who 
received a vaccine comprising 12 MPs revealed that addi-
tion of GM-CSF did not enhance immunostimulation [77]. 
Future avenues for the improvement of peptide vaccines 
include the use of modified adjuvants or long peptides, 
the inclusion of new antigens and combination therapy 
with other immunologically active agents [78]. Further-
more, optimization of the GM-CSF dose may be impor-
tant for inducing immunogenicity. There is evidence that 
repeated low doses of GM-CSF (40–80 μg for 1–5 days) 
can enhance vaccine-induced immune responses, but a det-
rimental effect is observed at higher doses (100–500 μg for 
1–5 days) [43]. This may be due to activation of anti-tumor 
responses at low doses, with higher doses inducing mobili-
zation of MDSCs from the bone marrow and causing sub-
sequent immune suppression [43]. Most studies of peptide 
vaccines evaluated here used a relatively high dose of GM-
CSF, which may not be optimal, and they did not investi-
gate MDSC activation. Overall, GM-CSF was well toler-
ated and did not have a detrimental effect on outcomes.
Generation of anti-GM-CSF antibodies could limit 
the activity of GM-CSF in vaccines and other treatments. 
Mice treated with adenoviruses and plasmids engineered 
to express GM-CSF produced neutralizing antibodies 
against GM-CSF that were associated with suppressed 
CD8+ T-cell responses [79]. When GM-CSF was given to 
patients with metastatic colorectal cancer, 95 % (19 of 20) 
developed anti-GM-CSF antibodies. In a subset of those 
patients, development of high-titer anti-GM-CSF responses 
was accompanied by a significant reduction in GM-CSF-
induced granulocytes, although the number of granulocytes 
did not decrease below baseline values [80]. More recently, 
a patient with glioblastoma developed grade 3 toxicity fol-
lowing treatment with a DC vaccine in combination with 
GM-CSF. This sensitization was associated with the pro-
duction of anti-GM-CSF antibodies and was reversed when 
GM-CSF treatment was stopped [81]. Although anti-GM-
CSF antibody production is rarely associated with clini-
cal symptoms, it may reduce the efficacy of GM-CSF in 
immunotherapy. Therefore, monitoring the development of 
anti-GM-CSF antibodies during clinical trials of GM-CSF 
should be considered. Spontaneous development of anti-
GM-CSF antibodies (in the absence of exogenous GM-
CSF) has been observed [82], and this should be taken into 
consideration when analyzing treatment-induced anti-GM-
CSF antibodies.
The use of GM-CSF as an adjuvant to surgery has shown 
some clinical benefit, including improvements in OS [54, 
55]. Although most patients in these studies were classified 
as having stage III–IV disease, they were considered to be 
disease-free at the time of study entry. Therefore, this pop-
ulation may be different from those who are not suitable 
for surgery, in that they were unlikely to have metastatic 
disease. Nonetheless, in patients with stage IIIC disease, 
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MSS was significantly improved in patients who received 
GM-CSF following complete surgical resection compared 
with those who did not receive GM-CSF [47]. Since the 
completion of this systematic review, a double-blind ran-
domized placebo-controlled phase 3 study has been pub-
lished in which patients with stage IV or high-risk stage III 
disease who had undergone surgical resection did not have 
significantly improved survival following treatment with a 
peptide vaccine, with or without GM-CSF, compared with 
placebo [83]. However, exploratory analyses revealed a 
trend toward improved OS in patients with resected vis-
ceral metastases who received GM-CSF compared with 
those who received placebo [83]. These results suggest that 
GM-CSF may be effective as an adjuvant treatment to sur-
gery in certain patients; this warrants further investigation.
Overall, GM-CSF in combination with peptide vac-
cines appears insufficient to induce an immune response 
that correlates with anti-tumor activity, whereas GM-CSF 
in combination with chemotherapy [56, 58, 59], autologous 
melanoma cell vaccine [66], ipilimumab [49] or recombi-
nant vaccinia virus [65] has shown induction of immune 
responses, together with evidence of some clinical activity, 
suggesting that use of GM-CSF may be beneficial in com-
bination with agents that stimulate the immune system suf-
ficiently to attack tumor cells.
This systematic review has several limitations. Few 
studies made direct comparisons between GM-CSF and 
other treatments, and most involved the use of GM-CSF 
as an adjuvant to other therapies. Therefore, it was often 
difficult to distinguish between the effect of the treatment 
and the effect of GM-CSF on clinical and immunological 
outcomes. Wide ranges of GM-CSF doses, treatment regi-
mens and comparators were evaluated in the included stud-
ies. Establishing the optimal dose of GM-CSF for adjuvant 
treatment is important to achieve the maximum response 
[43], and the range of dosing regimens employed by the 
studies reviewed here suggests that this is yet to be identi-
fied. There were also differences in the methodologies used 
to assess patient outcomes; hence, cross-study comparisons 
should be made with caution. The treatment groups were 
often small, making it difficult to extrapolate the results 
to the wider population of patients with advanced mela-
noma. Furthermore, GM-CSF is not approved for the treat-
ment of patients with melanoma, so the patient populations 
described here are likely to be highly selected and may not 
be representative of those in clinical practice.
In conclusion, it is clear that GM-CSF has been used as 
an adjuvant in many different clinical trial settings; how-
ever, evidence for clinical efficacy is controversial. Some 
clinical benefit has been observed in patients who received 
GM-CSF in combination with surgery, chemotherapy or 
immunomodulatory agents. In general, however, outcomes 
for patients receiving peptide vaccines were not improved 
when GM-CSF was used as an adjuvant. GM-CSF is a 
promising therapeutic adjuvant, but there is a lack of con-
trolled phase 3 trials investigating the direct effects of GM-
CSF in patients with advanced melanoma. Small, single-
center studies conducted mostly in academic institutions 
have not led to the design and implementation of well-
controlled phase 3 clinical studies. The results presented 
here indicate that further studies are needed to identify the 
optimal treatment regimen and effectiveness of GM-CSF in 
patients with advanced melanoma.
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